Blinded continuous monitoring in clinical trials with recurrent event endpoints

por Friede, Tim, Häring, Dieter A., Schmidli, Heinz
Publicado 2018

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II...

por Ghezzi, Angelo, Chitnis, Tanuja, K-Laflamme, Annik, Meinert, Rolf, Häring, Dieter A., Pohl, Daniela
Publicado 2019

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials

por Leppert, David, Kropshofer, Harald, Häring, Dieter A., Dahlke, Frank, Patil, Ashwini, Meinert, Rolf, Tomic, Davorka, Kappos, Ludwig, Kuhle, Jens
Publicado 2022

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis

por Langdon, Dawn W., Tomic, Davorka, Penner, Iris‐Katharina, Calabrese, Pasquale, Cutter, Gary, Häring, Dieter A., Dahlke, Frank, Kappos, Ludwig
Publicado 2021

Long-term prognostic value of longitudinal measurements of blood neurofilament levels

por Häring, Dieter A., Kropshofer, Harald, Kappos, Ludwig, Cohen, Jeffrey A., Shah, Anuja, Meinert, Rolf, Leppert, David, Tomic, Davorka, Kuhle, Jens
Publicado 2020

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

por Samjoo, Imtiaz A, Drudge, Christopher, Walsh, Sarah, Tiwari, Santosh, Brennan, Róisín, Boer, Ibolya, Häring, Dieter A, Klotz, Luisa, Adlard, Nicholas, Banhazi, Judit
Publicado 2023

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

por Dahlke, Frank, Arnold, Douglas L, Aarden, Piet, Ganjgahi, Habib, Häring, Dieter A, Čuklina, Jelena, Nichols, Thomas E, Gardiner, Stephen, Bermel, Robert, Wiendl, Heinz
Publicado 2021

Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis

por Graves, Jennifer S., Thomas, Marius, Li, Jun, Shah, Anuja R., Goodyear, Alexandra, Lange, Markus R., Schmidli, Heinz, Häring, Dieter A., Friede, Tim, Gärtner, Jutta
Publicado 2022

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

por Radue, Ernst-Wilhelm, Barkhof, Frederik, Kappos, Ludwig, Sprenger, Till, Häring, Dieter A., de Vera, Ana, von Rosenstiel, Philipp, Bright, Jeremy R., Francis, Gordon, Cohen, Jeffrey A.
Publicado 2015

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

por Kappos, Ludwig, De Stefano, Nicola, Freedman, Mark S, Cree, Bruce AC, Radue, Ernst-Wilhelm, Sprenger, Till, Sormani, Maria Pia, Smith, Terence, Häring, Dieter A, Piani Meier, Daniela, Tomic, Davorka
Publicado 2015

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial

por Bar-Or, Amit, Montalban, Xavier, Hu, Xixi, Kropshofer, Harald, Kukkaro, Petra, Coello, Neva, Ludwig, Inga, Willi, Roman, Zalesak, Martin, Ramanathan, Krishnan, Kieseier, Bernd C., Häring, Dieter A., Bagger, Morten, Fox, Edward
Publicado 2022

White matter lesion location correlates with disability in relapsing multiple sclerosis

por Gaetano, Laura, Magnusson, Baldur, Kindalova, Petya, Tomic, Davorka, Silva, Diego, Altermatt, Anna, Magon, Stefano, Müller-Lenke, Nicole, Radue, Ernst-Wilhelm, Leppert, David, Kappos, Ludwig, Wuerfel, Jens, Häring, Dieter A, Sprenger, Till
Publicado 2020

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

por Yu, Huixin, Graham, Gordon, David, Olivier J., Kahn, Joseph M., Savelieva, Marina, Pigeolet, Etienne, Das Gupta, Ayan, Pingili, Ratnakar, Willi, Roman, Ramanathan, Krishnan, Kieseier, Bernd C., Häring, Dieter A., Bagger, Morten, Soelberg Sørensen, Per
Publicado 2022

How patients with multiple sclerosis acquire disability

por Lublin, Fred D, Häring, Dieter A, Ganjgahi, Habib, Ocampo, Alex, Hatami, Farhad, Čuklina, Jelena, Aarden, Piet, Dahlke, Frank, Arnold, Douglas L, Wiendl, Heinz, Chitnis, Tanuja, Nichols, Thomas E, Kieseier, Bernd C, Bermel, Robert A
Publicado 2022

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

por Hauser, Stephen L., Kappos, Ludwig, Bar-Or, Amit, Wiendl, Heinz, Paling, David, Williams, Mitzi, Gold, Ralf, Chan, Andrew, Milo, Ron, Das Gupta, Ayan, Karlsson, Goeril, Sullivan, Roseanne, Graham, Gordon, Merschhemke, Martin, Häring, Dieter A., Vermersch, Patrick
Publicado 2023

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Tr...

por Ziemssen, Tjalf, Arnold, Douglas L., Alvarez, Enrique, Cross, Anne H., Willi, Roman, Li, Bingbing, Kukkaro, Petra, Kropshofer, Harald, Ramanathan, Krishnan, Merschhemke, Martin, Kieseier, Bernd, Su, Wendy, Häring, Dieter A., Hauser, Stephen L., Kappos, Ludwig, Kuhle, Jens
Publicado 2022

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

por Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig
Publicado 2022

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study

por Arnold, Douglas L, Banwell, Brenda, Bar-Or, Amit, Ghezzi, Angelo, Greenberg, Benjamin M, Waubant, Emmanuelle, Giovannoni, Gavin, Wolinsky, Jerry S, Gärtner, Jutta, Rostásy, Kevin, Krupp, Lauren, Tardieu, Marc, Brück, Wolfgang, Stites, Tracy E, Pearce, Gregory L, Häring, Dieter A, Merschhemke, Martin, Chitnis, Tanuja
Publicado 2020

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

por Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Das Gupta, Ayan, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, Kappos, Ludwig
Publicado 2022

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study

por Miller, David H., Lublin, Fred D., Sormani, Maria Pia, Kappos, Ludwig, Yaldizli, Özgür, Freedman, Mark S., Cree, Bruce A. C., Weiner, Howard L., Lubetzki, Catherine, Hartung, Hans‐Peter, Montalban, Xavier, Uitdehaag, Bernard M. J., MacManus, David G., Yousry, Tarek A., Gandini Wheeler‐Kingshott, Claudia A. M., Li, Bingbing, Putzki, Norman, Merschhemke, Martin, Häring, Dieter A., Wolinsky, Jerry S.
Publicado 2018